GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Tax Provision

Starton Therapeutics (Starton Therapeutics) Tax Provision : $0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Tax Provision?

Starton Therapeutics's tax provision for the three months ended in Jun. 2023 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.


Starton Therapeutics Tax Provision Historical Data

The historical data trend for Starton Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics Tax Provision Chart

Starton Therapeutics Annual Data
Trend Mar21 Mar22 Mar23
Tax Provision
- - -

Starton Therapeutics Quarterly Data
Mar21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23
Tax Provision Get a 7-Day Free Trial - - - - -

Starton Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Starton Therapeutics (Starton Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
215 College Road, Suite No.300, Paramus, NJ, USA, 07652
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines